With treatments for neuropsychiatric illnesses, such as schizophrenia, having remained the same for decades, a research consortium is changing the field with new studies, backed by new approaches and tools. Two studies from Mount Sinai push frontiers with single-cell analyses of brain tissue with schizophrenia and unraveling regulatory mechanisms of brain disease.